| Systematic identification of genomic markers of drug sensitivity in cancer cells MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ... Nature 483 (7391), 570-575, 2012 | 2551 | 2012 |
| mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 AC Faber, EM Coffee, C Costa, A Dastur, H Ebi, AN Hata, AT Yeo, ... Cancer discovery 4 (1), 42-52, 2014 | 141 | 2014 |
| Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer AC Faber, AF Farago, C Costa, A Dastur, M Gomez-Caraballo, R Robbins, ... Proceedings of the National Academy of Sciences 112 (11), E1288-E1296, 2015 | 136 | 2015 |
| Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors U McDermott, RY Ames, AJ Iafrate, S Maheswaran, H Stubbs, ... Cancer Research 69 (9), 3937-3946, 2009 | 113 | 2009 |
| Ligand-dependent PDGF receptor-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGF receptor kinase inhibitors U McDermott, RY Ames, AJ Iafrate, S Maheswaran, H Stubbs, ... Cancer research 69 (9), 3937, 2009 | 4 | 2009 |
| Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. EM Coffee, AC Faber, C Costa, A Dastur, H Ebi, AN Hata, AT Yeo, Y Song, ... Molecular Cancer Therapeutics 12 (11_Supplement), C263-C263, 2013 | | 2013 |
